Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves outcomes in HFmrEF/HFpEF across all KDIGO kidney risk categories.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!